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Therapeutic options for pulmonary arterial hypertension (PAH) have increased over
the last decades. The advent of pharmacological therapies targeting the prostacyclin,
endothelin, and NO pathways has significantly improved outcomes. However, for the
vast majority of patients, PAH remains a life-limiting illness with no prospect of cure.
PAH is characterised by pulmonary vascular remodelling. Current research focusses
on targeting the underlying pathways of aberrant proliferation, migration, and apo-
ptosis. Despite success in preclinical models, using a plethora of novel approaches
targeting cellular GPCRs, ion channels, metabolism, epigenetics, growth factor recep-
tors, transcription factors, and inflammation, successful transfer to human disease
with positive outcomes in clinical trials is limited. This review provides an overview
of novel targets addressed by clinical trials and gives an outlook on novel preclinical
perspectives in PAH.
Abbreviations: 6MWD, 6-min walk distance; ALK1, activin receptor-like kinase 1; ANP, atrial natriuretic peptide; ASK1, apoptosis signal-regulating kinase 1, MAP3K5; Bcl-2, B-cell lymphoma 2;
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DNA methyltransferase; E2, oestradiol; ERAs, endothelin receptor antagonists; FDA, U.S. Food and Drug Administration; FHIT, fragile histidine triad; FKBP12, FK506-binding protein; FOX,
forkhead box protein; HDACs, histone deacetylases; HIF, hypoxia-inducible factor; HMGB1, high mobility group box-1; IPAH, idiopathic pulmonary arterial hypertension; KCNK3, potassium
channel subfamily K member 3 gene; mPAP, mean pulmonary arterial pressure; mTOR, mechanistic target of rapamycin; NAD+, nicotinamide adenine dinucleotide; NFAT, nuclear factor of
activated T-cells; Nrf2, nuclear factor erythroid 2-related factor 2; p21, cyclin-dependent kinase inhibitor 1; p27, cyclin-dependent kinase inhibitor 1B; PA, pulmonary artery; PAEC, pulmonary
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1 | DEFINITION AND CLASSIFICATION OF
PULMONARY HYPERTENSION
Pulmonary hypertension (PH) was defined until recently by an ele-
vated mean pulmonary arterial pressure (mPAP) of ≥25 mmHg (Galie
et al., 2015). However, as the mPAP in healthy subjects was deter-
mined to be 14.0 ± 3.3 mmHg (Kovacs, Berghold, Scheidl, &
Olschewski, 2009), the upper limit of normal, defined as two SDs
above the mean value, mPAP should not exceed 20 mmHg
(Simonneau et al., 2019). In the past, the relevance of the arbitrary
definition of PH with a mPAP ≥25 mmHg has been questioned. Values
>20 mmHg have clinical impact and affect outcome in populations at
risk for PH (e.g., patients with systemic sclerosis; Simonneau
et al., 2019; Valerio, Schreiber, Handler, Denton, & Coghlan, 2013).
Thus, new cut-off values to define PH were suggested at the 6th
World Symposium on PH in Nice 2018 defining PH as a mPAP
>20-mmHg concomitant with a pulmonary vascular resistance
(PVR) ≥ 3 Wood Units (WU) for pre-capillary forms of PH to account
for the effect of cardiac output (CO) and pulmonary arterial wedge
pressure (PAWP) on mPAP [PVR = (mPAP-PAWP)/CO] (Simonneau
et al., 2019). It is currently unknown whether patients with mPAP
between 21 and 24 mmHg and PVR ≥3 Wood Units would benefit
from vasoactive treatment.
PH is currently classified into five separate groups with distinct
pathophysiological characteristics (Galie et al., 2015). The clinical clas-
sification underwent minor revision at the 6th World Symposium (see
Table 1; Simonneau et al., 2019). It ranges from rare forms such as
pulmonary arterial hypertension (PAH, Group 1) and PH due to pul-
monary artery obstructions (Group 4, primarily chronic thromboem-
bolic PH [CTEPH]), to more common usually mild elevations of
pressure seen in significant cardiac (PH due to left heart disease,
Group 2) and respiratory disease (PH due to lung diseases and/or hyp-
oxia, Group 3) and PH with unclear and/or multifactorial mechanisms
(Group 5). The present review article will focus exclusively on PAH.
PAH has multiple causes but symptoms are similar in all forms of
PAH, although their evolution and pattern vary depending on the
aetiology. The most common symptoms are progressive breathless-
ness, fatigue, syncope, and clinical signs of heart failure. The diagnosis
is usually first suggested by echocardiography. Confirmation of PAH
requires right heart catheterisation and a systematic approach to
investigation (Galie et al., 2015) including extensive imaging (Kiely
et al., 2019) and integration with clinical features, to enable accurate
classification which defines treatment. It is anticipated that advances
in genotyping, improved imaging, and the application of artificial intel-
ligence approaches to analysing data sets will aid refinement of dis-
ease classification and aid the study of treatment interventions. An
overview of important landmarks in PAH research is given in Figure 1.
2 | OVERVIEW OF PATHOGENETIC
MECHANISMS IN PAH
Pathological alterations have been recently reviewed in detail
(Humbert et al., 2019). The initial concept that PAH is largely caused
by mechanisms of vasoconstriction has been expanded over the last
decades to a more complex picture in which multiple genetic, epige-
netic, and environmental mechanisms lead to pulmonary vascular
remodelling (Humbert et al., 2019). In some regards, PAH may even
be considered as a pseudo-malignant disease with similar features to
cancer (apoptotic resistance, altered metabolism, and overexpression
of growth factor receptors; Boucherat, Vitry, et al., 2017). It is now
accepted that curative therapeutic approaches must address not only
vasoconstriction but also vascular remodelling, by inhibiting prolifera-
tive and activating anti-proliferative mechanisms (reverse remodelling;
El Kasmi et al., 2014).
Pulmonary vascular remodelling underlying PAH is characterised
by medial hypertrophy/hyperplasia, intimal and adventitial fibrosis,
(in situ) thrombotic lesions, and plexiform lesions, as well as peri-
vascular infiltration of inflammatory cells (B- and T-lymphocytes, mast
cells, dendritic cells, macrophages, etc.; Humbert et al., 2019). It
affects mainly distal muscular-type pulmonary arterial vessels and
small pre-capillary arterioles (with diameters of 70–500 μm and
20–70 μm, respectively, in humans), but also to a varying degree post-
capillary veins and bronchial arteries. The mechanisms for the latter
are incompletely understood but may be connected by bronchial
arterio-venous shunting (Humbert et al., 2019).
There is evidence demonstrating that all cell types of the vascular
wall (fibroblasts, pulmonary arterial endothelial cells [PAEC], pulmo-
nary arterial smooth muscle cells [PASMC], myofibroblasts, and peri-
cytes) contribute to pulmonary vascular remodelling (Humbert
et al., 2019). Several triggering factors combined with gen-
etic/epigenetic susceptibility can initiate a phenotypical change of
PAEC and PASMC characterised by apoptosis resistance, increased
proliferation, and migration (Humbert et al., 2019). Damage of PAEC
may play a particular role in the initiation of this process. Despite
overabundance and/or overactivation of several pro-angiogenic
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TABLE 1 Clinical classification of PH and haemodynamic definitions (World Symposium on PH, Nice 2018)
Classification Haemodynamicsa Therapy
Group 1: PAH
1.1 Idiopathic PAH
1.2 Heritable PAH
1.2.1 BMPR2 mutations
1.2.1 other mutations (ALK1, endoglin
[with or without hereditary
haemorrhagic telangiectasia])
1.3 Drug- and toxin-induced PAH
1.4 PAH associated (APAH) with
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH long-term responders to calcium
channel blockers
1.6 PAH with overt features of
venous/capillaries involvement
(pulmonary veno-occlusive
disease/pulmonary capillary
haemangiomatosis)
1.7 Persistent PH of the newborn
syndrome
Pre-capillary
mPAP > 20 mmHg
PAWP ≤ 15 mmHg
PVR ≥ 3 WU
Specific pulmonary vasoactive drugs
Supportive therapy
APAH: therapy of underlying disease
Group 2: PH due to left heart disease
2.1 PH due to heart failure with
preserved LVEF
2.2 PH due to heart failure with reduced
LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular
conditions leading to post-capillary PH
Isolated post-capillary
mPAP > 20 mmHg
PAWP > 15 mmHg
Combined pre-/post-capillary
mPAP > 20 mmHg
PAWP > 15 mmHg
PVR ≥ 3 WU
Therapy of underlying disease
Group 3: PH due to lung diseases and/or
hypoxia
3.1 Obstructive lung disease
3.2 Restrictive lung disease
3.3 Other lung disease with mixed
restrictive/obstructive pattern
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders
Pre-capillary
mPAP > 20 mmHg
PAWP ≤ 15 mmHg
PVR ≥ 3 WU
Severe PH:
mPAP ≥ 35 mmHg
Therapy of underlying disease
Oxygen supplementation
Group 4: PH due to pulmonary artery
obstructions
4.1 Chronic thromboembolic PH
4.2 Other pulmonary artery obstructions
4.2.1 Sarcoma (high or intermediate
grade) or angiosarcoma
4.2.2 Other malignant tumours
4.2.3 Non-malignant tumours
4.2.4 Arteritis without connective tissue
disease
4.2.5 Congenital pulmonary artery
stenoses
4.2.6 Parasites: Hydatidosis
Pre-capillary
mPAP > 20 mmHg
PAWP ≤ 15 mmHg
PVR ≥ 3 WU
Anticoagulationb
Pulmonary endarterectomyb
Balloon pulmonary angioplastyb
Specific pulmonary vasoactive drugsb
Group 5: PH with unclear and/or
multifactorial mechanisms
5.1 Haematological disorders: chronic
haemolytic anaemia, myeloproliferative
disorders
5.2 Systemic and metabolic disorders:
pulmonary Langerhans cell
Pre-capillary
mPAP > 20 mmHg
PAWP ≤ 15 mmHg
PVR ≥ 3 WU
Isolated post-capillary
mPAP > 20 mmHg
Therapy of underlying disease
(Continues)
SOMMER ET AL. 3
pathways, angiogenesis and pericyte-associated tube formation of
endothelial cells is disturbed leading to progressive obliteration of
pre-capillary arteries (“vascular pruning” or “dead-tree” picture;
Humbert et al., 2019; Yuan et al., 2015). Furthermore, fibroblasts
become hyperproliferative and are involved in remodelling of the
extracellular matrix promoting the alterations of PASMC and PAEC, as
well as increasing stiffness of the large elastic main, lobar, and seg-
mental pulmonary arteries (Humbert et al., 2019).
PAH is a multifactorial and heterogeneous disease in which multi-
ple and different pathogenetic alterations have been observed in simi-
lar phenotypes (Figure 2): (1) Environmental trigger factors include air
pollution (Sofianopoulou et al., 2019), as well as (particularly for PH
Group 3) hypoxia and smoke exposure, shear stress (PH Group 1.4.4)
and infections (PH Groups 1.4.2 and 1.4.5). (2) Different mutations
leading to genetic susceptibility (bone morphogenetic protein
receptor 2 [BMPR2], activin receptor-like kinase 1 [ALK1], voltage-
gated potassium channel 1.5 [Kv1.5], and potassium channel
subfamily K member 3 [KCNK3]) have been identified, and early life
epigenetic imprinting may also play a role. (3) PAH is promoted or trig-
gered by systemic and circulating factors such as hormones and
metabolites, as well as a pro-coagulatory and inflammatory disposi-
tion, particularly in PH Group 1.4.1. (4) Endothelial dysfunction leads
to an imbalanced release of endothelial factors (endothelin, Tx, NO,
and prostacyclin) and is currently targeted by PAH therapy. Further
endothelial mechanisms include reduced anticoagulatory endothelial
properties, increased expression of adhesion molecules (E-selectin,
intercellular adhesion molecule 1, and vascular cell adhesion
molecules), and endothelial release of different chemokines, cyto-
kines, and growth factors (Huertas et al., 2018). (5) Cellular mecha-
nisms in PAEC, PASMC, and fibroblasts include altered
expression/function of ion channels and growth factor receptors, acti-
vation or deactivation of transcription factors (e.g., nuclear factor of
F IGURE 1 History of PH and development of therapeutic drugs. FDA, U.S. Food and Drug Administration; WHO, World Health Organisation
TABLE 1 (Continued)
Classification Haemodynamicsa Therapy
histiocytosis, Gaucher disease,
glycogen storage disease,
neurofibromatosis, sarcoidosis
5.3 Others: chronic renal failure with or
without haemodialysis, fibrosing
mediastinitis
5.4 Complex congenital heart disease
PAWP > 15 mmHg
PVR < 3 WU
Combined pre-/post-capillary
mPAP > 20 mmHg
PAWP > 15 mmHg
PVR ≥ 3 WU
Note. Grey shading means main post-capillary form of PH.
Abbreviations: ALK, activin receptor-like kinase; APAH, associated pulmonary arterial hypertension; BMPR, bone morphogenic protein receptor; HIV,
human immunodeficiency virus; LVEF, left ventricular ejection fraction; PAH, pulmonary arterial hypertension.
aAccording to the 6th World Symposium on PH (Simonneau et al., 2019).
bTreatment of chronic thromboembolic PH requires a multifaceted approach which may include multiple interventions.
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activated T-cells [NFAT], hypoxia-inducible factor [HIF] 1, signal trans-
ducer and activator of transcription [STAT] 3, and forkhead box pro-
tein [FOX] O1), and dysregulated cellular metabolism. (6) Finally,
repair mechanisms counteracting remodelling are disturbed, including
DNA and endothelial repair mechanisms (Boucherat, Vitry,
et al., 2017; Humbert et al., 2019).
The multifactorial nature of PAH may be one of the reasons why
finding a cure for PAH is challenging. For example, despite the impor-
tance of BMPR2 in the pathobiology of PAH, disease penetrance in
carriers is only ~20% (higher in females than males), indicating that
other factors are required for development of the phenotype. There
are currently studies ongoing in large populations with idiopathic PAH
(IPAH) and heritable PAH to identify further mutations or polymor-
phisms that could represent a “second hit.” Several candidates have
been identified, including variants in the prostacyclin synthase gene
and mutations in the potassium voltage-gated channel sub-family A
member 5 gene (Ghataorhe et al., 2017).
3 | CURRENT TREATMENT OPTIONS
IN PAH
Treatment of PAH currently includes supportive therapy such as
diuretics, supervised rehabilitation, birth control advice, and oxygen
supplementation, if needed (Ulrich et al., 2019). Pharmacological
therapies targeting the pulmonary vasculature are currently only
approved for patients with PAH (Group 1) and selected patients with
CTEPH (Group 4). In other forms of PH, clinical trials using therapies
approved for PAH have yet to demonstrate benefit, and current treat-
ment strategies aim to optimise therapy of the underlying disease (see
Table 1).
In PAH, current pharmacological therapies target three pathways
regulating endothelial factors with vasoconstrictive/vasodilatory and
proliferative/mitogenic properties: (1) NO-cGMP signalling is targeted
by PDE5 inhibitors (tadalafil and sildenafil) and a soluble GC stimula-
tor (riociguat); (2) endothelin receptor antagonists (ERAs) target both
ETA and ETB receptors non-selectively (bosentan) or ETA receptors
selectively (ambrisentan and macitentan. This selectivity may be
advantageous because stimulation of ETA receptors causes vasocon-
striction whereas stimulation of ETB receptors causes vasodilation);
and (3) prostacyclin signalling is increased by either parenteral prosta-
cyclin analogues (epoprostenol, treprostinil, and iloprost) or an orally
available IP receptor agonist (selexipag; Galie et al., 2015). Milestones
in the development of PAH therapies are shown in Figure 1, and piv-
otal studies are summarised in Table 2. In addition, a small group of
patients with idiopathic, heritable, or drug-induced PAH who respond
to a vasodilator challenge with a significant drop in pulmonary artery
pressures and who have a sustained response to high-dose calcium
channel blockade (around 5–10% of patients with IPAH) have excel-
lent long-term survival (Rich, Kaufmann, & Levy, 1992; Sitbon
F IGURE 2 Patho-mechanisms underlying PAH. For details, please refer to text. DMT, DNA methyltransferase; ET, endothelin; Fb, fibroblasts;
IC, immune cell; IL1R1, IL-1 receptor type 1; PA, pulmonary artery; PV, pulmonary veins; SiMFis, singular millimetric fibrovascular lesions
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TABLE 2 Clinical trials in PAH
Trial name and identification
number Type of trial Primary endpoint
Reference or trial duration/start
date and status
A. Landmark clinical trials in PAH positive for primary endpoint and resulting in approval of therapy
Continuous infusion of i.v.
epoprostenol
RCT: 81 patients with IPAH Change in 6MWD and PVR Barst R.J., N Engl J Med 1996; 334:
296–301
Continuous s.c. infusion of
treprostinil
RCT: 470 patients with PAH Change from baseline in 6MWD at
12 weeks
Simonneau G. et al., Am J Respir
Crit Care Med 2002; 165: 800–
804
Aerosolised iloprost (AIR) RCT: 203 treatment-naïve patients
with mixed types of PH
An increase of at least 10% in
6MWD and 1 NYHA FC at
12 weeks
Olschewski H. et al., N Engl J Med
2002; 347: 322–329
Bosentan (BREATHE-1) RCT: 213 treatment-naïve patients
with either IPAH or CTD-PAH
Change from baseline in 6MWD at
16 weeks
Rubin L.J. et al. N Engl J Med 2002;
346: 896–903
Sildenafil (SUPER) RCT: 278 treatment-naïve patients
with PAH
Change from baseline in 6MWD at
Week 12
Galiè N. et al., N Engl J Med 2005;
353: 2148–2157
Ambrisentan (ARIES-1 and
ARIES-2)
RCT: 202 (ARIES-1) and 192
(ARIES-2) treatment-naïve
patients with PAH
Change from baseline in 6MWD at
Week 12
Galiè N. et al., Circulation 2008;
117: 3010–3019
Tadalafil (PHIRST-1) RCT: 405 treatment-naïve or
pretreated patients with PAH
Change from baseline in 6MWD at
Week 16. Endpoint not met in
pretreated patients
Galiè N. et al., Circulation 2009;
119: 2894–2903
Inhaled treprostinil (TRIUMPH I) RCT: 235 pretreated patients with
PAH
Change from baseline in 6MWD at
12 weeks
McLaughlin V. et al., J Am Coll
Cardiol 2010; 55: 1915–1922
Macitentan (SERAPHIN) RCT: 742 treatment-naïve or
pretreated patients with PAH
Time from initiation of treatment
to first occurrence of a
composite morbidity or mortality
endpoint
Pulido T. et al., N Engl J Med 2013;
369: 809–818
Riociguat (PATENT-1/2) RCT: 443 treatment-naïve or
pretreated patients with PAH
Change from baseline in 6MWD at
Week 12
Ghofrani H.A. et al. N Engl J Med
2013; 369: 330–340
Selexipag (GRIPHON) RCT: 1156 treatment naïve or
pretreated patients with PAH
Time from initiation of treatment
to first occurrence of a
composite morbidity or mortality
endpoint
Sitbon O. et al N Engl J Med 2015;
373: 2522–2533
Clinical trials of up-front combination therapy in PAH positive for primary endpoint
Ambrisentan and tadalafil in
combination versus
montherapy (AMBITION)
RCT: 500 treatment naïve patients
with PAH
Time from initiation of treatment
to first occurrence of a
composite morbidity or mortality
endpoint
Galie N. et al., N Engl J Med 2015;
373: 834–844
B. Trials in PAH not positive for primary endpoint, terminated early or other results
Terguride: 5-HT receptor
antagonist
Phase 2 trial: 78 patients with PAH Change from baseline in PVR at
Week 16
Ghofrani et al., 2012 (abstract)
Endpoint not reached
Nilotinib: TK inhibitor (AMN107)
NCT01179737
Phase 2 trial: 23 patients with PAH Change from baseline in PVR at
6 months
2010–2014
Terminated due to serious adverse
event
Aspirin and simvastatin: COX
and HMG-CoA-reductase
inhibitor
Phase 2 trial: 92 patients with PAH Change from baseline in 6MWD at
6 months
Kawut S.M. et al., Circulation 2011;
123 (25): 2985–2993
Endpoint not reached
Atorvastatin: HMG-CoA-
reductase inhibitor (APATH)
Phase 2 trial: 220 patients with
PAH and CTEPH
Change from baseline in 6MWD at
24 weeks
Zeng W.J. et al., 2012; 40 (1): 67–
74
Endpoint not reached
Inhaled aviptadil: VIP Phase 2 trial: 56 patients with PAH Change in PVR acute or after
3 months
Published as abstract: Galiè et al.,
Am J Respir Crit Care Med 2010;
181: A2516
(Continues)
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TABLE 2 (Continued)
Trial name and identification
number Type of trial Primary endpoint
Reference or trial duration/start
date and status
Said S.I., Am J Respir Crit Care Med
2012 Apr 1; 185 (7): 786; author
reply 786
Endpoint not reached
Imatinib: TK inhibitor (QTI571;
IMPRES)
Phase 3 trial: 202 patients with
PAH
Change from baseline in 6MWD at
Week 24
Hoeper M.M. et al., Circulation
2013; 127 (10): 1128–1138.
Endpoint reached but safety
concerns
Selonsertib: ASK1 inhibitor
(ARROW)
Phase 2 trial: 150 patients with
PAH
Change from baseline in PVR at
Week 24
Published as abstract: Boucherat
O. et al., Am J Respir Crit Care
Med 197 (3): 284–286, 2018
Endpoint not reached
FK506: calcineurin inhibitor
(tacrolimus)
Phase 2 trial: 23 patients with PAH Frequency of adverse events
during 16 weeks
Spiekerkoetter E. et al., Eur Respir J.
2017; 50 (3)
Low-level FK506 is well tolerated
and increases BMPR2 in subsets
of patients with PAH
Pioglitazone: dipeptidyl
peptidase 4 inhibitor
NCT00825266
Phase 2 trial: 2 patients with PAH Insulin resistance profile change at
Week 16
2009–2017
Terminated (difficulty in finding
eligible patients)
Ubenimex: aminopeptidase
inhibitor (LIBERTY1/2)
NCT02664558/
NCT02736149
Phase 2 trial: 61/51 patients with
PAH
Change from baseline in PVR at
Week 24/frequency of adverse
events
2016–2018
Terminated due to failure of
efficacy
Racecadotril: neprilysin inhibitor Phase 2 trial: 21 patients with PAH Maximum change in circulating
ANP concentration after 14 days
Hobbs A.J. et al. Br J Pharmacol
2019 May; 176 (9): 1251–1267
Increase in ANP
Anakinra: IL-1 inhibitor Phase 1 trial: 7 patients with PAH VO2max, VE/VCO2 slope at
14 days
Trankle C.R. et al., Am J Respir Crit
Care Med 2019; 199 (3): 381–
384
Endpoint not reached
Ambrisentan plus
spironolactone: ERA plus
aldosterone antagonist
NCT02253394
Phase 4 trial: 30 patients with PAH Cardiopulmonary fitness at
200 days
2014–2019
Terminated (low enrolment)
Fulvestrant: oestrogen
antagonist NCT02911844
Phase 2 trial: 5 patients with PAH Change from baseline in oestradiol,
tricuspid annular plane systolic
excursion, 6MWD, and N-
terminal pro-brain natriuretic
peptide at 9 weeks
Kawut S.M. et al., Ann Am Thorac
Soc. 16 (11): 1456–1459, 2019
No significant changes of
endpoints
Tocilizumab: anti-IL-6 antibody
(TRANSFORM-UK)
NCT02676947
Phase 2 trial: 29 patients with PAH Adverse events; change from
baseline in PVR at 6 months
2016–2018
Completed, results posted online
Endpoint not reached
C. Current ongoing clinical trials on PAH
Clinical trials of up-front combination therapy in PAH using licensed therapies
Macitentan and tadalafil and
selexipag versus macitentan
and tadalafil in combination
(TRITON) NCT02558231
RCT: 238 treatment naïve patients
with PAH
Change from baseline in PVR at
Week 26
2016
Recruiting
Hormonal modulators
Anastrozole: aromatase inhibitor
(PHANTOM) NCT03229499
Phase 2 trial: 84 patients with PAH Change from baseline in 6MWD at
6 months
2017
Recruiting
Phase 2 trial: 24 patients with PAH 2018
Recruiting
(Continues)
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TABLE 2 (Continued)
Trial name and identification
number Type of trial Primary endpoint
Reference or trial duration/start
date and status
Tamoxifen: oestrogen receptor
inhibitor (T3PAH)
NCT03528902
Change from baseline in tricuspid
annular plane systolic excursion
at Week 24
DHEA (EDIPHY) NCT03648385 Phase 2 trial: 24 patients with PH Change in RV longitudinal strain
between DHEA and placebo at
Weeks 18 and 40
2018
Recruiting
Spironolactone: aldosterone
antagonist NCT01712620
Phase 2 trial: 70 patients with PAH Change from baseline in 6MWD at
6 months
2012
Recruiting
rhACE2: GSK2586881
NCT03177603
Phase 2 trial: 24 patients with PAH Change from baseline in PVR up to
4 hr
2017
Recruiting
KAR5585: tryptophan
hydroxylase 1 inhibitor
NCT02746237
Phase 1 trial: 120 healthy
individuals
Adverse events up to 4 days 2016–2016
Completed, results pending
Escitalopram: SSRI
NCT00190333
Phase 3 trial: 30 patients with PH Change from baseline in 6MWD at
Week 16
2005–2008
Completed, results pending
Fluoxetine: SSRI NCT03638908 Phase 2 trial: 8 patients with WHO
group 1 PH
Change from baseline in PVR at
Week 24
2018
Active, not recruiting
PB1046: VIP analogue
NCT03315507
Phase 1 trial: 10 patients with
WHO group 1 PH
Adverse events 28 days after last
dose, laboratory parameters,
change in PVR
2017
Active, not recruiting
GPCR pathways
Apelin (EXAP) NCT01590108 Phase 1 trial: 12 healthy individuals
and patients with IPAH
Cardiopulmonary performance at
6 months
2012–2019
Completed, results pending
Mitochondrial and metabolic adaptations
Ranolazine: sodium channel
inhibitor, partial FAO inhibitor
NCT01839110
Phase 4 trial: 22 patients with PAH Change in RVEF by MRI at
6 months
2013–2019
Completed, results pending
Ranolazine NCT02829034 Phase 4 trial: 22 patients with PAH Change from baseline in RVEF by
MRI at Week 26
2016–2019
Completed, results pending
Trimetazidine: FAO inhibitor
NCT02102672
Phase 2 trial: 25 patients with PAH Changes in RV function assessed
by 3D echo at 3 months
2014
Recruitment state unknown
Metformin: biguanide
NCT03617458
Phase 2 trial: 160 patients with
PAH
Change from baseline in 6MWD at
Week 12
2018
Recruiting
Ferinject or CosmoFer: iron
infusion NCT01447628
Phase 2 trial: 40 patients with PAH Change from baseline in PVR and
endurance at Week 12
2011–2019
Completed, results pending
Epigenetic alterations and interaction with metabolic pathway
Olaparib: PARP inhibitor
(OPTION) NCT03782818
Phase 1 trial: 20 patients with PAH Adverse events at Week 24 2019
Not yet recruiting
Apabetalone: BRD4 inhibitor
(APPRoAcH-p) NCT03655704
Phase 1 trial: 10 patients with PAH Change from baseline in PVR at
Week 16
2019
Not yet recruiting
Oxidative stress related pathways
Bardoxolone methyl: IκB kinase
and NF-κB inhibitor, Nrf2
activator (LARIAT)
NCT02036970
Phase 2 trial: 166 patients with PH Change from baseline in 6MWD at
Week 16
2014–2019
Completed, results pending
Bardoxolone methyl (CATALYST)
NCT02657356
Phase 3 trial: 200 patients with
CTD-PAH
Change from baseline in 6MWD at
Week 24
2016
Recruiting
Bardoxolone methyl (RANGER)
NCT03068130
Phase 3 trial: 414 patients with PH Long-term safety up to 5 years 2017
Recruiting
CXA-10: nitrated fatty acid
compound (PRIMEx)
NCT03449524
Phase 2 trial: 96 patients with PAH Change in RVEF and PVR at
6 months
2018
Recruiting
(Continues)
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et al., 2005). This serves to illustrate the heterogeneous nature of
IPAH and the importance of developing a personalised approach to
drug therapy.
Recent improvements in outcomes for patients with PAH reflect
a move to the use of combination drug therapy targeting multiple
pathways. An overview of clinical trials of combination therapy in
PAH was recently provided (Humbert & Ghofrani, 2016). Current
treatment algorithms are based on interval multiparameter risk assess-
ment with the aim of achieving a low-risk status (Galie et al., 2019).
Lung transplantation remains an important therapeutic option for
patients deteriorating despite maximal medical therapy. Despite treat-
ment advances and an increase in survival by more than twofold dur-
ing the last two decades, PAH remains a fatal disease, and the
identification of new targets and development of new therapies is
required.
4 | NOVEL TREATMENT OPTIONS
TARGETING SPECIFIC PATHWAYS IN PAH
Preclinical and clinical research on novel drugs currently focusses on
PAH where typical characteristics of pulmonary vascular remodelling
exist. This review describes novel concepts that have been established
in preclinical models and have been transferred to clinical trials
(Figure 3; ongoing clinical trials are summarised in Table 2). Further-
more, some very new studies on preclinical approaches are described.
Although preclinical models only partly reflect features of PAH, they
have been successfully used to test treatment options in PAH. The
most common preclinical models are the chronic hypoxic model of the
mouse and rat leading to rather mild PH without characteristic plexi-
form lesions, the combined application of hypoxia and the VEGF
inhibitor Sugen 5416 (Sugen/hypoxia) in rats which is characterised
by more severe PH including plexiform lesions, and the monocrotaline
model of rats which is largely driven by inflammatory stimuli and cau-
ses severe PH (Stenmark, Meyrick, Galie, Mooi, & McMurtry, 2009).
Several other models with knockdown of relevant pathways have
been described, but none of the models reproduces all the histopatho-
logical patterns of PAH.
4.1 | Circulating hormones
4.1.1 | Sex hormones
Systemic factors, mainly hormones or nutrients, may either trigger
or promote the development of PAH. The best known hormone-
TABLE 2 (Continued)
Trial name and identification
number Type of trial Primary endpoint
Reference or trial duration/start
date and status
Inflammatory mediators
Rituximab: anti-CD20 antibody
NCT01086540
Phase 2 trial: 58 patients with
systemic sclerosis associated-
PAH
Change in PVR at Week 24 2010
Active, not recruiting
Elafin: elastase-specific protease
inhibitor NCT03522935
Phase 1 trial: 30 healthy individuals Adverse events at 28 days 2018
Recruiting
Growth factor receptors
Sotatercept: activin receptor
type 2A fusion protein acting
as a ligand trap (SPECTRA)
NCT03738150
Phase 2 trial: 25 patients with PAH Change from baseline in VO2 max
at Week 24
2018
Recruiting
Sotatercept (PULSAR)
NCT03496207
Phase 2 trial: 100 patients PAH Change from baseline in PVR at
Week 24
2018
Recruiting
Transcriptional factors
ABI-009: mTOR inhibitor
NCT02587325
Phase 1 trial: 25 patients with PAH Adverse events at Week 16 2015
Recruiting
Stem cell therapy
Allogeneic cardiosphere-derived
stem cells NCT03145298
Phase 1 trial: 26 patients with PAH Primary safety endpoints within
72 hr of infusion
2017
Recruiting
eNOS-enhanced EPCs
NCT03001414
Phase 2 trial: 45 patients with PAH Change from baseline in 6MWD at
Month 6
2016
Recruiting
Abbreviations: 6MWD, 6-min walk distance; ANP, atrial natriuretic peptide; ASK1, apoptosis signal-regulating kinase 1; BRD4, bromodomain-containing
protein 4; CTD-PAH, connective tissue disease-associated pulmonary arterial hypertension; DHEA, dehydro-epiandrosterone; eNOS, endothelial NOS;
EPCs, endothelial progenitor cells; FAO, fatty acid oxidation; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; mTOR, mechanistic target of rapamycin; Nrf2,
nuclear factor erythroid 2-related factor 2; NYHA FC, New York Heart Association functional classification; RCT, randomised controlled trial; rhACE2,
recombinant human ACE2; RVEF, right ventricular ejection fraction; SSRI, selective serotonin reuptake inhibitor; VE/VCO2, minute ventilation/carbon diox-
ide production; VIP, vasoactive intestinal peptide; VO2max, maximal oxygen uptake.
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related phenomenon in this regard is the “oestrogen paradox”:
Women have a higher incidence of IPAH and heritable PAH than
men, but female patients with PAH have better outcomes than
male patients. The role of different oestradiol (E2) metabolites and
receptors is not completely elucidated. Some of the metabolites
have proliferative effects (e.g., 16α-hydroxyoestrone), while others
also have anti-proliferative and anti-inflammatory properties
(e.g., 2-hydroxyoestradiol and 2-methoxyoestradiol). High E2 levels
were associated with PAH in male patients and reduced exercise
capacity in female patients, but E2 may also have protective
effects on the right ventricle (RV; recently reviewed in Tofovic &
Jackson, 2019). Thus, different levels of E2 and its metabolites at
different disease stages could explain sex-dependent differences.
Moreover, genes of the Y-chromosome are up-regulated in PH and
have protective anti-remodelling properties in hypoxic mice (Umar
et al., 2018). Decreasing circulating E2 by inhibiting conversion of
androgens to E2 using the aromatase inhibitor anastrozole and
inhibition of the E2 receptor with tamoxifen inhibited PH in differ-
ent animal models of PH, partly in a sex-dependent way
(Tofovic & Jackson, 2019). By contrast, supplementation with E2
increased exercise capacity in male and female rats with severe
PH, probably by exerting protective effects on the RV (Lahm
et al., 2016). Most importantly, anastrozole showed good safety
and tolerability in male and female patients with PAH in a small
“proof-of-principle” trial and significantly reduced E2 levels and
improved 6-min walk distance (6MWD) but not RV function
(Kawut et al., 2017). These pilot data supported initiation of the
randomised, controlled PH and Anastrozole Trial (PHANTOM;
ClinicalTrials.gov identifier: NCT03229499). Furthermore, the effect
of oestrogen inhibition with tamoxifen will be investigated in
patients with PAH in a small randomised controlled trial (RCT;
Tamoxifen Therapy to Treat PAH [T3PAH]; ClinicalTrials.gov identi-
fier: NCT03528902). In contrast to anastrozole, tamoxifen can be
used in pre-menopausal female patients without inducing meno-
pause. An open-label trial of the oestrogen antagonist fulvestrant
(ClinicalTrials.gov identifier: NCT02911844) was recently
completed. However, due to the low number of participants, no
final conclusions on the effects of fulvestrant on PAH can be
drawn. Nevertheless, it was generally well tolerated (Kawut
et al., 2019).
4.1.2 | Dehydroepiandrosterone
Dehydroepiandrosterone (DHEA) is a steroid hormone that serves
as a precursor for both oestrogen and testosterone synthesis.
DHEA prevented and reversed PH and RV dysfunction in different
animal models of PH (Lahm, Tuder, & Petrache, 2014). Accordingly,
higher levels of E2 and lower levels of DHEA were associated with
increased risk of PAH in men (Ventetuolo et al., 2016) and
increased risk and severity of PAH in post-menopausal women
(Baird et al., 2018). DHEA treatment significantly improved 6MWD,
F IGURE 3 Novel treatment options in PAH. Substances shown in the Figure are currently tested in clinical trials. For details, please refer to
text. EPCs, endothelial progenitor cells; ERs, oestrogen receptors; LTA4H, LTA4 hydrolase; SERT, 5-HT (serotonin) transporter; VPAC, vasoactive
intestinal peptide receptor
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pulmonary haemodynamics, and diffusion capacity of patients with
PH associated with chronic obstructive pulmonary disease, without
worsening gas exchange (de La Roque et al., 2012). Currently,
DHEA is being tested in a crossover trial in a small number of
patients with PAH (Effects of DHEA in PH [EDIPHY]; ClinicalTrials.
gov identifier: NCT03648385). The primary outcome is change in
RV longitudinal strain, as determined by cardiac MRI.
4.1.3 | Renin–angiotensin–aldosterone system
The concept of transferring therapeutic approaches from the sys-
temic to the pulmonary circulation has refocussed attention on the
role of the neurohumoral and renin–angiotensin–aldosterone sys-
tems (Maron & Leopold, 2015). Antagonists of the receptor for
aldosterone, a steroid hormone that binds the mineralocorticoid
receptor in the heart and pulmonary vasculature, have been used
for fluid management in PAH. In animal studies, aldosterone antag-
onists attenuated or partially reversed PH (Preston et al., 2013).
However, despite the potential of aldosterone antagonists to exert
beneficial effects on the RV and pulmonary vasculature beyond
their diuretic properties, no RCT has yet evaluated their efficacy in
PAH. The “Combination Ambrisentan Plus Spironolactone in Pulmo-
nary Arterial Hypertension Study” (CAPS-PAH)—a crossover study
investigating whether addition of spironolactone to ambrisentan
affects exercise capacity in patients with PAH—was terminated
because of low enrolment (ClinicalTrials.gov identifier:
NCT02253394). Another RCT will examine the effect of spi-
ronolactone on 6MWD and clinical worsening in patients with
PAH (ClinicalTrials.gov identifier: NCT01712620).
Another novel approach addresses the peptidase ACE2 which
converts the peptide hormones angiotensin I and angiotensin II to
their vasodilator derivates (angiotensin-(1–9) and angiotensin-(1–7),
respectively) with a preference for angiotensin II degradation. How-
ever, ACE2 may also degrade other vasodilatory factors such as
apelin (see below; Kazemi-Bajestani, Patel, Wang, & Oudit, 2012).
Decreased ACE2 levels and ACE2 autoantibodies have been
reported in PAH (Tan, Liao, Zhou, Mei, & Wong, 2018). An open-
label pilot study on acute haemodynamic responses after a single
infusion of recombinant human ACE2 in patients with PAH showed
improved CO without a significant change in mPAP or systemic
pressures, and reduced markers of oxidant and inflammatory stress
(Hemnes et al., 2018). A dose-escalation study in PAH is currently
recruiting patients (ClinicalTrials.gov identifier: NCT03177603).
4.1.4 | Atrial natriuretic peptide
Atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) are released from atrial cardiomyocytes or the ventricles
respectively. Natriuretic peptides increase renal sodium excretion,
cause vasodilation via cGMP release, and decrease heart fibrosis.
Natriuretic peptides are degraded by the metalloprotease
neprilysin. Recently, a combination of the angiotensin receptor
blocker valsartan and the neprilysin inhibitor sacubitril was
approved for treatment of left heart failure (McMurray
et al., 2014). The combination treatment was used because
neprilysin degrades not only natriuretic peptides but also vasocon-
strictive factors such as endothelin and angiotensin II. Studies of
neprilysin in animal models of PH showed conflicting results. While
neprilysin-deficient mice exhibited an exaggerated response to
chronic hypoxia (Dempsey et al., 2009), pharmacological inhibition
of neprilysin alone or in combination with PDE5 inhibition attenu-
ated PH in chronic hypoxic rats without affecting systemic circula-
tion (Baliga et al., 2008; Thompson, Sheedy, & Morice, 1994).
Recently, the efficacy and safety of the neprilysin inhibitor
racecadotril was tested in an RCT in PAH. Acute administration
increased plasma ANP and cGMP levels and slightly decreased
PVR. Similar to the ACE2 trial, mPAP did not change significantly,
indicating that the decrease in PVR was mostly driven by an
increase in CO. Systemic BP was not decreased significantly, and
plasma endothelin levels did not change following exposure to
racecadotril (Hobbs et al., 2019). Further studies are necessary to
investigate the effect of these vasodilators on PAH.
4.1.5 | Neurohormonal regulation
Neurohormonal regulation plays an important role in pulmonary
vascular tone and RV function (Maron & Leopold, 2015). In fact,
β-blockers (β-adrenoceptor antagonists) are one of the main treat-
ment strategies in left ventricular systolic dysfunction and may
thus have a place in PAH therapy (beyond their indication for sup-
raventricular tachycardia which is a frequent co-morbidity in PAH).
Animal studies suggest that β-blockers may have beneficial effects
on RV dysfunction and maladaptive remodelling. It has also been
suggested that some β-blockers have favourable effects on the pul-
monary vasculature in PAH (reviewed in Ameri et al., 2016).
Although β-blocker use in PAH was long regarded as non-benefi-
cial, careful administration in stable PAH without decompensated
heart failure was recently shown to have acceptable safety. Several
small studies tested the effect of β-blockers on RV function and
functional capacity with different outcomes. Thus, larger and longer
studies are required to establish which patients (if any) might bene-
fit from specific β-blockers in PAH. Currently, the use of β-blockers
is not recommended in patients with PAH unless required for co-
morbidities (Perros et al., 2017). More recently, the impact of sym-
pathetic denervation of the pulmonary arteries has been examined;
Chinese investigators demonstrated a drop in pulmonary artery
pressure using catheter radiofrequency ablation (Chen et al., 2013).
Although serious concerns were raised regarding the study design
and patient characteristics (Galie & Manes, 2013), a clinical trial is
ongoing to examine intravascular ultrasound-directed pulmonary
artery denervation in patients on dual oral combination therapy
(Treatment of PH 1 Study [TROPHY1]; ClinicalTrials.gov identifier:
NCT02835950/NCT02516722).
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4.1.6 | 5-HT
5-HT (serotonin) has been implicated in the development of PAH
since anorexigens, which increase the availability of 5-HT by inducing
its release from platelets and inhibiting its reuptake and degradation
by MAO, were noted to increase the risk of PAH (Abenhaim
et al., 1996). Inhibition of the 5-HT2A and 5-HT2B receptors can inhibit
development of PH in mouse models (Delaney et al., 2018; West
et al., 2016). Nevertheless, the 5-HT2A and 5-HT2B receptor inhibitor
terguride showed no clinical benefit in a Phase 2 study in PAH
(Ghofrani et al., 2012), possibly because the 5-HT1B receptor is the
most highly expressed 5-HT receptor in the pulmonary arteries in
PAH and mediates PASMC proliferation in humans (Lythgoe
et al., 2016). However, pre-specified subgroup analysis indicated an
improvement of PVR in patients on PAH background therapy with
ERAs (Ghofrani et al., 2012). Thus, further studies are planned with a
selective inhibitor of tryptophan hydroxylase 1 (TPH1) which is the
rate-limiting enzyme in 5-HT biosynthesis. In preclinical PH models,
the TPH1 inhibitor significantly reduced PH and showed an additive
effect when applied together with ambrisentan, but not tadalafil
(Aiello et al., 2017). A clinical Phase 1 study with the TPH1 inhibitor
KAR5585 (ClinicalTrials.gov identifier: NCT02746237) showed a good
safety profile and a decrease in circulating 5-HT (Paralkar et al., 2017).
Furthermore, a trial with the 5-HT uptake inhibitor escitalopram was
completed in 2008, but no results were published (ClinicalTrials.gov
identifier: NCT00190333). Another trial with the selective 5-HT
uptake inhibitor fluoxetine is planned (ClinicalTrials.gov identifier:
NCT03638908), although a recent analysis using the “Registry to
Evaluate Early and Long-term PAH Disease Management” (REVEAL)
showed that incident selective 5-HT uptake inhibitor use was
associated with increased mortality and a greater risk of clinical wors-
ening, albeit without adjustment for all confounders (Sadoughi
et al., 2013).
4.1.7 | Other hormones
Several other hormones have effects on the cardiopulmonary system.
One of the long-standing hormones investigated in the field of PAH is
vasoactive intestinal peptide (VIP), a peptide hormone that stimulates
contractility in the heart and causes dilation of smooth muscles of dif-
ferent organs, including blood vessels. Despite failure of a previous
clinical trial with inhaled administration of VIP (Said, 2012), a future
study with a s.c. injected, sustained-release analogue of VIP (PB1046)
is planned (ClinicalTrials.gov identifier: NCT03315507), because there
were serious concerns that the inhaled route of administration may
have affected the outcome negatively (Lythgoe et al., 2016). The best
examples of endocrine dysfunction in PAH are thyroid disorders,
which are common in PAH and associated with poor prognosis
(Simonneau et al., 2019).
In summary, there are multiple approaches to balance the hor-
monal state in PAH. However, despite promising preliminary results,
potential beneficial (and non-beneficial) effects of hormones
independent of their action on the pulmonary vasculature/RV need to
be carefully investigated.
4.2 | GPCR pathways
4.2.1 | Rho-associated protein kinase
Rho-associated protein kinase (ROCK) belongs to the family of
serine–threonine kinases and can be activated via the GTPase RhoA
by several cellular receptors, including GPCRs which are stimulated by
various vasoactive substances such as angiotensin II or 5-HT. ROCK is
involved in many cellular functions, for example, smooth muscle cell
contraction, cell migration, and stress fibre formation, and has been
implicated in the pathogenesis of PAH (Antoniu, 2012). ROCK inhibi-
tors have shown promising results in animal studies (Antoniu, 2012).
However, in a clinical trial, the 6MWD was not improved by the
ROCK inhibitor fasudil (Fukumoto et al., 2013). Novel ROCK inhibi-
tors are under development (Vaidya et al., 2017).
4.2.2 | Apelin
Apelin is an endogenous vasodilatory and inotropic peptide acting via
the G protein-coupled apelin receptor. Apelin is down-regulated in
human PAH and can inhibit PH in animal models. Use of apelin for
PAH might be challenging due to its short t1/2 and systemic
vasodilatory effect (Kazemi-Bajestani et al., 2012; Kim, 2014). The
effect of apelin infusion on cardiopulmonary performance in healthy
volunteers and patients with IPAH was recently investigated in a small
clinical trial (ClinicalTrials.gov identifier: NCT01590108). Results are
still pending.
4.2.3 | Novel preclinical targets
Future approaches may include activation of NO release and inhibi-
tion of RhoA/ROCK signalling by activation of the G protein-coupled
adenosine A2A receptor (Alencar, Montes, Barreiro, Sudo, & Zapata-
Sudo, 2017). Salidroside, an active ingredient isolated from Rhodiola
rosea, inhibited chronic hypoxia-induced PH and pulmonary arterial
remodelling by increasing A2A receptor expression and enhancing A2A
receptor-related mitochondria-dependent apoptosis (Huang
et al., 2015). Another potential target is the Wnt/planar cell polarity
pathway which involves the Frizzled family of GPCRs. Activation of
the Wnt/planar cell polarity pathway was recently shown to be
required for the establishment of human pulmonary endothelium-
pericyte interactions. Loss of Wnt/planar cell polarity signalling could
reduce the viability of newly formed vessels in PAH and thus contrib-
ute to vascular pruning. Interestingly, mice lacking endothelial expres-
sion of Wnt5a showed a similar response to chronic hypoxia as wild-
type mice but failed to recover after re-exposure to normoxia (Yuan
et al., 2019).
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4.3 | Ion channels
Ion channels are crucial for cellular calcium homeostasis and thus reg-
ulate vasoconstriction and calcium-dependent transcription factors,
but they also regulate cytosolic concentrations of other ions
(e.g., potassium) which contribute to cellular survival. Dysregulated
cell-type-specific ion channels have been extensively described in
PAH and include potassium channels, different types of transient
receptor potential channels, calcium sensor proteins, and chloride
channels (Boucherat et al., 2015; Lambert et al., 2018). Moreover, the
identification of novel heterozygous loss-of-function mutations in the
KCNK3 gene in PAH has drawn attention to channelopathies as
underlying mechanisms (Ma et al., 2013). in vivo pharmacological acti-
vation of KCNK3 had beneficial effects in monocrotaline-induced PH,
demonstrating therapeutic relevance (Antigny et al., 2016). Very
recent studies also suggest a role for glutaminergic NMDA receptors
(Dumas et al., 2018). Despite these promising preclinical approaches,
clinical trials addressing ion channels are currently lacking in PAH.
4.4 | Mitochondrial and metabolic adaptation
4.4.1 | Cellular metabolic alterations—The
Warburg effect
The Warburg effect has been described in different animal models of
PH (Bonnet et al., 2006; McMurtry et al., 2004), and several studies in
humans have underlined the relevance of mitochondrial dysfunction
and metabolic alterations in PAH (Farha et al., 2016; Rhodes
et al., 2017; Xu et al., 2007). As the Warburg effect was originally
described in cancer cells, its discovery in PH essentially contributed to
the concept of the “cancer-hypothesis” in PAH (Archer et al., 2008).
The Warburg effect is characterised by a switch of cellular metabolism
from glucose oxidation to glycolysis despite the presence of oxygen
and provides metabolic intermediates for macromolecule synthesis.
Metabolic intermediates from the tricarboxylic acid cycle (e.g., acetyl-
CoA or oxidised nicotinamide adenine dinucleotide [NAD+]) can sup-
port epigenetic alterations thereby promoting proliferation (see
below).
The picture of mitochondrial alterations in PH is becoming
increasingly detailed, including mitochondrial hyperpolarization,
dysbalanced mitochondrial fission and fusion, altered mitochondrial
calcium handling due to decreased expression of the mitochondrial
calcium uniporter and disturbed interaction with the endoplasmic
reticulum, increased glutaminolysis and accumulation of mitochondrial
heat shock protein 90 (Boucherat et al., 2018; reviewed in detail in
Chan & Rubin, 2017, and Culley & Chan, 2018). Most importantly, a
causative role for mitochondrial alterations in the development of PH
has been supported by the fact that targeting mitochondrial alter-
ations, for example, using dichloroacetate (DCA), which promotes glu-
cose oxidation, or the mitochondrial fission inhibitor Mdivi or by
inhibiting fatty acid oxidation, inhibited PH in animal models (Chan &
Rubin, 2017; Culley & Chan, 2018).
Encouraged by the promising preclinical results, an open-label
clinical trial was performed to test the effect of DCA in patients with
IPAH (Michelakis et al., 2017). After 4 months of DCA treatment, the
average mPAP and PVR decreased and functional capacity increased,
but some of the patients did not respond to treatment. Four of the
20 patients withdrew from the study due to neuropathic side effects
(all of them from the highest dose group). Detailed analysis showed
that lack of treatment response was associated with loss-of-function
polymorphisms of specific genes that affect mitochondrial metabolism
(sirtuin 3 [SIRT3] and uncoupling protein 2 [UCP2]). Interestingly, mice
deficient in UCP2 exhibited PH under baseline conditions (Dromparis
et al., 2013; Pak et al., 2013). SIRT3 deficiency has also been con-
nected to spontaneous development of PH (Paulin et al., 2014), but
animal studies have not been completely consistent (Waypa
et al., 2013). The role of SIRT3 is described in more detail in Sec-
tion 4.6. Although the DCA trial only showed limited treatment
effects, it was an important step to show the feasibility of mitochon-
drial targeted therapy in PH and to demonstrate the practical use of
individualised therapy. Further large-scale studies are needed to
investigate the efficacy of DCA in specific patients at different doses.
However, DCA may not be optimal for PAH treatment, because of its
rapid clearance, highly variable exposure (with individually varying
inactivation by GSH transferase zeta 1) and small therapeutic window
(Rowlands, 2016), as well as the dose-limiting risk of neuropathy in
adults. Further research is necessary to identify novel mitochondrial
targets or optimised alternatives to DCA as a promising approach for
treatment of PAH.
The concept of mitochondrial dysfunction in PAH has also
been applied to the RV, with promising preclinical results (see
Chan & Rubin, 2017). However, one must consider that altering
mitochondrial function may have opposing effects on the RV and
pulmonary vasculature. For example, although UCP2 deficiency is
associated with spontaneous PH and RV dysfunction under base-
line conditions (Esfandiary et al., 2019; Pak et al., 2013),
UCP2-deficient mice show better RV adaptation to increased
afterload (induced by pulmonary arterial banding) than wild-type
mice (Esfandiary et al., 2019). More details on mitochondrial dys-
function and anti-apoptotic mechanisms were recently summarised
by Boucherat, Vitry, et al. (2017).
4.4.2 | Systemic metabolic alterations
PAH has been associated with glucose intolerance and insulin
resistance. Glucose intolerance was found to be a predictor of
mortality in PAH (Belly et al., 2012). A more detailed study
recently showed similar glucose intolerance in patients with PAH
and controls when matched for the metabolic syndrome, but pro-
found alterations in lipid metabolism and lipid-related insulin resis-
tance (Hemnes et al., 2019). It remains unclear if these alterations
contribute to the pathogenesis of PH or are consequences of
PH. Nevertheless, optimisation of blood glucose level may have
beneficial effects in PAH, although this has not yet entered the
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guidelines for PAH treatment beyond optimal standard of care for
diabetes. Several clinical trials now address this question in PAH
and PH due to heart failure with preserved ejection fraction. A
Phase 2 clinical trial is investigating the impact of 12 weeks of
metformin treatment on 6MWD and further functional parameters,
RV and left ventricular performance, and several metabolic and
hormonal parameters (ClinicalTrials.gov identifier: NCT03617458).
Inhibitors of dipeptidyl peptidase 4 (gliptins) which increase
glucagon-like peptide 1 (GLP-1) and insulin release may also be of
interest; sitagliptin alleviated PH induced by monocrotaline,
bleomycin, or hypoxia in rats (Xu et al., 2018). The GLP-1 receptor
agonist liraglutide both prevented and reversed monocrotaline-
induced PH, RV hypertrophy, and pulmonary vascular wall
remodelling (Lee et al., 2016). The concept of using statins to
improve PAH by addressing systemic lipid metabolism has been
unsuccessful (Kawut et al., 2011; Zeng et al., 2012).
Another concept identified in the guidelines for PAH treatment is
related to iron metabolism. Although the underlying mechanisms are
not completely understood, a recent open-label study showed that
i.v. iron supplementation in patients with PAH increased exercise
endurance capacity, although 6MWD was not changed significantly
(Ruiter et al., 2015). This study included only patients without anae-
mia, and blood Hb content did not change significantly after iron infu-
sion. In this regard, several groups have shown that iron deficiency in
the absence of anaemia is common and associated with reduced sur-
vival in PAH (Rhodes et al., 2011). Another pilot study demonstrated
an increase in 6MWD in patients with PAH and iron deficiency receiv-
ing i.v. iron supplementation compared with matched patients without
iron deficiency who did not receive iron supplementation. However,
Hb levels were also increased in the treated patients (Viethen
et al., 2014). A double-blind study of iron infusion in iron-deficient
patients with PAH was recently completed, and results are pending
(ClinicalTrials.gov identifier: NCT01447628).
4.5 | Epigenetic alterations and interaction with
metabolic pathways
The role of epigenetics in PAH is a fast-growing field of research. The
major epigenetic phenomena include DNA methylation, histone modi-
fications, and modulations of non-coding RNAs (reviewed in
Chelladurai et al., 2019; Pullamsetti, Perros, Chelladurai, Yuan, &
Stenmark, 2016). Despite encouraging preclinical studies, few of them
have reached the clinical stage in PAH yet, mostly because their mod-
ulation is often associated with unwanted effects and strategies to
therapeutically deliver non-coding RNA mimics or inhibitors to the
lungs remain in their infancy (Meloche, Paulin, Provencher, &
Bonnet, 2015).
Recently, clinical interest in histone deacetylase (HDAC) inhibi-
tion in PAH has been rekindled by the discovery that the cytosolic
HDAC6 is involved in both pulmonary arterial remodelling and RV fail-
ure (Boucherat, Chabot, et al., 2017). This isoenzyme represents an
important pharmacological target for selective inhibition that may
reduce the toxicity related to the off-target effects of pan-HDAC
inhibitors previously described in PAH (Bogaard et al., 2011). Other
HDACs known as Sirtuins are also implicated in PAH. The Sirtuins are
NAD+-dependent HDACs regulating important metabolic pathways
involved in many biological processes such as cell survival, prolifera-
tion, apoptosis, DNA repair, and cell metabolism all of which are criti-
cal to PAH development. Consistent with these findings, mice lacking
SIRT3, a mitochondrial deacetylase, have increased acetylation and
inhibition of many mitochondrial enzymes and complexes, suppressing
mitochondrial oxidative metabolism. These mice spontaneously
develop PH; a loss-of-function SIRT3 polymorphism is associated with
PAH development in humans (Paulin et al., 2014). The importance of
this metabolism–epigenetics axis has been further highlighted by the
recent clinical trial results using DCA, a pyruvate dehydrogenase
kinase inhibitor known to promote glucose oxidation (see above). The
DCA trial showed that functional variants of SIRT3 and UCP2 largely
influenced the clinical and haemodynamic response to DCA
(Michelakis et al., 2017). Although not fully understood, the down-
regulation of both SIRT1 and SIRT3 in PAH might also result from
activation of PARP-1 (Meloche et al., 2014), which could cause deple-
tion of NAD+ (SIRT substrate) levels, which inhibits SIRT1 activity
(Meloche et al., 2014). Inhibition of PARP1 in conjunction with stan-
dard combination therapy (ERA + PDE5 inhibitor) in an experimental
PH model showed greater efficacy than standard combination therapy
alone (Meloche et al., 2014), and thus, the U.S. Food and Drug
Administration-approved PARP1 inhibitor olaparib is under clinical
investigation in the Olaparib for PAH study (OPTION; ClinicalTrials.
gov identifier: NCT03782818).
The epigenetic/metabolism/DNA damage response axis
described above in PAH is very similar to that described in cancer.
This cancer theory of PAH (Boucherat, Vitry, et al., 2017) is further
reinforced by the implication of the newly described epigenetic
reader, bromodomain-containing protein 4 (BRD4), in PAH. Similar
to cancer cells in which BRD4 has been shown to promote several
oncogenes implicated in PAH pathogenesis, including c-Myc, B-cell
lymphoma 2 (Bcl-2), cyclin-dependent kinase inhibitor 1 (p21),
cyclin-dependent kinase inhibitor 1B (p27), Runt-related transcrip-
tion factor 2 (RUNX2), and FOXM1 (Belkina & Denis, 2012), we
recently documented that BRD4 is significantly overexpressed in
human PAH, accounting for the up-regulation of the oncogenic
NFAT, Bcl-2, Survivin, and p21 and triggering the proliferation/apo-
ptosis imbalance in PAH-PASMCs (Meloche et al., 2015; Meloche
et al., 2017). BRD4 was similarly up-regulated in PH rat models in
which its inhibition improved pulmonary haemodynamics, RV func-
tion, and distal pulmonary arterial remodelling. Although these
effects were attributed to the modulation of NFAT, Bcl-2, Survivin,
and p21, other mechanisms cannot be excluded. The mechanisms
accounting for BRD4 inhibitor efficacy in PAH are the subject of
numerous published and ongoing preclinical studies. In addition to
its effects on the cancer-like phenotype of PASMCs, the inhibition
of autoimmune-mediated/inflammatory vascular injuries,
RUNX2-mediated pro-calcification processes, and its influence on
metabolism and DNA damage are suggested mechanisms of
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therapeutic intervention by BRD4 inhibitors in PAH. Recently, a
clinically available BRD4 inhibitor reversed PH in two independent
animal studies potentially through FOXM1 (Van der Feen
et al., 2019). Altogether, these findings support a therapeutic role
for BRD4 inhibitors in PAH, which is currently being explored in
the Apabetalone for PAH Pilot Study (APPRoAcH-p; ClinicalTrials.
gov identifier: NCT03655704).
4.6 | Oxidative stress-related pathways
Oxidative stress has been implicated in the development of PAH,
although animal studies in this regard are inconclusive, depending
on the model used (Fulton et al., 2017). Increased mitochondrial
ROS release might be more relevant for RV remodelling than PH,
at least in the hypoxic mouse model (Pak et al., 2018). Increased
levels of markers of oxidatively modified proteins
(e.g., nitrotyrosine), fatty acids (e.g., malondialdehyde), and DNA
have been detected in lung sections, plasma, or urine of patients
with PAH (Bowers et al., 2004; Cracowski et al., 2001; Irodova,
Lankin, Konovalova, Kochetov, & Chazova, 2002) but the clinical
relevance remains unclear. A small open-label clinical trial with the
antioxidant ubiquinol showed a reduction of indirect signs of oxida-
tive stress and right atrial pressure after 3 months of treatment,
but no alterations of BNP/6MWD could be detected (Sharp
et al., 2014). Non-specific inhibition of ROS may result in disap-
pointing outcomes, because low levels of ROS are necessary to
maintain physiological cellular functions.
The pleiotropic effects of ROS on metabolism and inflammation
in PH were recently explored. Inhibition of apoptosis signal-
regulating kinase 1 (ASK1; MAP3K5) a serine/threonine kinase that is
activated by oxidative stress, promoting inflammation, ROS produc-
tion, proliferation, fibrosis, apoptosis, mitochondrial damage, and,
under certain contexts, insulin resistance) reduced pathological
remodelling and halted progression of PH in rodent models (Budas
et al., 2018). Despite these encouraging results, a Phase 2 study
(ClinicalTrials.gov identifier: NCT02234141) evaluating the ASK1
inhibitor selonsertib did not achieve its primary endpoint in PAH
(Boucherat, Provencher, & Bonnet, 2018). Conversely, a Phase 2 clini-
cal trial evaluating bardoxolone, an activator of the nuclear factor ery-
throid 2-related factor 2 (Nrf2), a transcription factor that regulates
antioxidant proteins and suppresses activation of the pro-
inflammatory factor NF-κB, showed significant improvements in exer-
cise capacity in PAH (LARIAT; ClinicalTrials.gov identifier:
NCT02036970), albeit mainly in connective tissue disease (CTD)-
associated PAH (Oudiz et al., 2017). Thus, a follow-up trial in patients
with CTD-PAH was initiated (CATALYST; ClinicalTrials.gov identifier:
NCT02657356), and a Phase 3 clinical trial evaluating long-term
safety of bardoxolone in patients with PAH is ongoing (RANGER;
ClinicalTrials.gov identifier: NCT03068130). Results of a Phase 2 clini-
cal trial evaluating CXA-10, another Nrf2 activator and NF-κB sup-
pressor, are also pending (PRIMEx; ClinicalTrials.gov identifier:
NCT03449524).
4.7 | Inflammatory mediators
4.7.1 | Immune modulators in PAH
Immune modulation is an established concept in PAH, but classic anti-
inflammatory drugs such as corticosteroids or acetylsalicylic acid have
shown beneficial effects only in specific forms of PAH (Sanchez,
Sitbon, Jais, Simonneau, & Humbert, 2006) or no beneficial effects
(Kawut et al., 2011). However, interest in the field has been revived
by an improved understanding of immune regulation in PAH and the
notion that perivascular inflammatory infiltrates (macrophages, B-cells,
T-cells, and dendritic cells) often precede structural pulmonary vascu-
lar remodelling (Tamosiuniene et al., 2011). Histopathological studies
have demonstrated the presence of complement system components,
autoantibodies, and inflammatory cells (neutrophils) in the vessel
lumen, which can bind to the endothelium and may infiltrate the
medial muscular layer. The inflammatory infiltrate in the neointimal
layer is composed of T- and B-lymphocytes, with macrophages, mast
cells, and dendritic cells present in the adventitial layer. Lymphoid fol-
licles, characterised by T-cells, B-cells, and plasmacytoid dendritic
cells, are found in the periadventitial space (see Rabinovitch,
Guignabert, Humbert, & Nicolls, 2014). Although current knowledge
of the immune system is far from complete, increasing evidence sug-
gests that excessive local secretion of inflammatory mediators by pul-
monary vascular cells (e.g., IL-1β, IL-6, LTB4, macrophage migration
inhibitory factor, leptin, and TNF-α) as well as dysregulated immune
responses (innate [through macrophages and monocytes] and adap-
tive [impaired T-regulatory cell function and T-helper 17 cell immune
polarisation]) are major drivers of pulmonary remodelling in PAH with
or without autoimmune diseases (see Kuebler, Bonnet, &
Tabuchi, 2018; Rabinovitch et al., 2014).
Several immune modulatory approaches have been successfully
tested in animal models, including an IL-1 receptor antagonist, IL-6
antibodies, mycophenolate, dexamethasone, cyclosporine,
tacrolimus, LTB4 pathway inhibitors, and TNF-related apoptosis-
inducing ligand (Rabinovitch et al., 2014), but none have yet made the
transition to treatment of human PAH beyond CTD-PAH. However,
several clinical trials addressing immune modulation are ongoing,
including a clinical trial of the anti-CD20 monoclonal antibody
rituximab (which targets B-lymphocytes) in PAH associated with sys-
temic sclerosis (ClinicalTrials.gov identifier: NCT01086540). Rituximab
is often used to treat conditions for which there is a clonal source of
autoantibodies. Interestingly, plasmablasts in IPAH displayed clonal
expansions similar to those observed in autoimmune disease (Blum
et al., 2018). Anakinra is a recombinant IL-1 receptor antagonist used
to treat rheumatoid arthritis. The safety of anakinra in PAH was
recently evaluated in an open-label study. After 14 days of treatment,
high-sensitivity C-reactive protein and symptom burden were signifi-
cantly reduced (Trankle et al., 2019). The recently completed trial of
the IL-6 inhibitor tocilizumab in PAH (TRANSFORM-UK;
ClinicalTrials.gov identifier: NCT02676947) showed no significant
change in PVR from baseline at 6 months in the 19 patients who com-
pleted the study protocol (published online at https://www.
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clinicaltrialsregister.eu/ctr-search/trial/2015-002799-26/results). A
Phase 2 open-label extension study with ubenimex was recently ter-
minated after the original study failed to demonstrate efficacy
(ClinicalTrials.gov identifier: NCT02736149). A different approach
uses the endogenous protein elafin which inhibits the neutrophil-
derived serine proteases elastase and proteinase-3. Elafin reduced or
reversed PH in rats exposed to hypoxia or Sugen/hypoxia respectively
(Nickel et al., 2015; Zaidi, You, Ciura, Husain, & Rabinovitch, 2002).
Elafin has now progressed to a clinical trial in healthy volunteers
(ClinicalTrials.gov identifier: NCT03522935).
4.7.2 | Novel preclinical approaches
Recently, it was reported that fucoidan, a polysaccharidic ligand of the
adhesion molecule P-selectin, exhibits anti-proliferative properties
and can attenuate hypoxia-induced PH in mice. P-selectin is
expressed on endothelial cells and is involved in recruitment of leuko-
cytes and platelets to areas of inflammation and vascular injury
respectively (Novoyatleva et al., 2019). Moreover, the damage-
associated high mobility group box-1 (HMGB1)—which is secreted
from immune cells, activates macrophages as well as lymphocytes,
and triggers autoimmunity by binding to the toll-like receptor 4 (
TLR4)—was shown to be involved in development of PH. Expression
of both HMGB1 and TLR4 was elevated in the lungs of patients with
PAH. An inhibitor of binding between HMGB1 and TLR4 reduced PH
severity and mortality in animal models, even when given to animals
with established disease (Goldenberg et al., 2019). Thus, further novel
pathways involved in inflammation may be exploited in future for
treatment of PH.
4.8 | Growth factor receptors
Receptor TKs (RTKs) and the TGFβ superfamily of growth factor
receptors are both critically involved in PAH.
4.8.1 | RTKs
RTKs are cell surface receptors for growth factors, cytokines and hor-
mones. RTKs which have been implicated in PAH include PDGF, EGF,
FGF, VEGF, and nerve growth factor receptors. Upon activation by
growth factors, RTKs dimerise and become autophosphorylated. Bind-
ing of factors such as Src and PLCγ leads to activation of several
downstream kinases including PI3K/PKB (Akt), MAPKs, PKC, JAK,
STAT, and cyclin-dependent kinases (Lemmon & Schlessinger, 2010).
Several RTK inhibitors are used to treat different kinds of cancer,
including imatinib, dasatinib, and nilotinib (inhibiting the PDGF
receptor), the multikinase inhibitors sorafenib and sunitinib (inhibiting
the PDGF and VEGF receptors), and nilotinib (inhibiting the BCR-ABL
TK; Lemmon & Schlessinger, 2010). The PDGF receptor inhibitor
imatinib was the first RTK used in clinical PAH and the first drug used
in PAH to directly target vascular remodelling. However, despite
reducing PVR and increasingmean placebo-corrected 6MWD (by 32m)
in a clinical Phase 3 trial (Imatinib in PAH, a Randomised Efficacy
Study [IMPRES]), imatinib was not approved for PAH owing to an
unfavourable risk–benefit ratio; the imatinib-treated group did not
improve time to clinical worsening and showed subdural haematoma
in eight patients receiving both imatinib and anticoagulation with vita-
min K antagonists (Hoeper et al., 2013). However, treatment with
imatinib is currently the only approach beyond the classical, approved
and mainly vasodilator therapy that was shown to offer considerable
benefit at least in specific patients (Ghofrani et al., 2010; Ghofrani,
Seeger, & Grimminger, 2005; Hoeper et al., 2013). Thus, interest in
further trials with imatinib and defining groups of patients with an
optimal risk–benefit ratio remains high. Moreover, the efficacy of
imatinib opened the door to the quest for alternative RTKs with more
favourable profiles. Unfortunately, none of the tested RTKs met
expectations. A clinical trial with nilotinib was terminated due to
severe adverse events (ClinicalTrials.gov identifier: NCT01179737).
Exposure to dasatinib was even associated with the development of
PAH (Guignabert et al., 2016; Montani et al., 2012). Nintedanib was
unsuccessful in animal models and when used to treat single patients
with PAH on a compassionate basis (Richter et al., 2018). Sorafenib
was tested in an open-label study and showed some efficacy
(improvement of BNP, uric acid and cardiothoracic ratio of more than
10% from the original value continued for 1 month) in two out of nine
patients. However, CO also decreased in most patients treated with
sorafenib, raising serious concerns about further trials of sorafenib in
PAH (Kimura et al., 2017; Weatherald, Humbert, Guignabert, &
Montani, 2017). A similar decrease of CO was observed in a previous
open-label 1b trial (Gomberg-Maitland et al., 2010).
4.8.2 | TGFβ superfamily of growth factors
An imbalance in TGFβ/bone morphogenetic protein (BMP) signalling
has long been known as an important pathogenetic mechanism in
PAH, since mutations in BMPR2, a TGFβ receptor (TGFβR) subtype,
were identified in heritable PAH in 2000 (Lane et al., 2000). Recently,
heterozygous mutations of BMPR2 were identified in 15.3% of
patients from a U.K. PAH cohort (76% in familial PAH, 12% in spo-
radic cases, and 8% in anorexigen-exposed PAH cases; Graf
et al., 2018). Decreased BMPR2 signalling has also been detected in
patients with PAH without BMPR2 mutations. However, attempts to
address TGFβ pathways therapeutically have only recently been trans-
ferred to the clinic.
TGFβ/BMP signalling is transduced by a combination of different
type I (ALK1 to ALK7) and type II (e.g., TGFβR2, BMPR2, and activin
2A and 2B receptors) receptors as well as co-receptors (betaglycan
and endoglin). These multicomponent receptors activate canonical
downstream signalling via either Smad 2/3 (e.g., through TGFβR2 or
activin receptors together with ALK1, ALK2, ALK3, or ALK6) or Smad
1/5/8 (e.g., through BMPR2 or activin receptors together with ALK4,
ALK5, or ALK7), or non-canonical signalling via different kinases
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(e.g., LIM domain kinase 1). Different ligands (e.g., TGFβ, BMPs, and
activin) can activate the receptors with different affinity and induce
partially opposing effects with regard to development of PAH. While
activation of Smad 2/3 signalling (e.g., by TGFβ) results in gene
expression promoting PAH, activation of Smad 1/5/8 signalling
(e.g., by BMPs) inhibits alterations associated with PAH such as vascu-
lar smooth muscle growth (Rol, Kurakula, Happe, Bogaard, &
Goumans, 2018). Thus, inhibition or activation of the respective
receptor pathway may represent a promising strategy to treat PAH,
although balancing the response might be challenging due to over-
lapping ligand and receptor functions.
The most straightforward therapeutic approach may be activation
of BMPR2-Smad 1/5/8 signalling using BMPR2 receptor agonists
(e.g., specific ligands) or inhibitors of degradation of BMPR2, such as
chloroquine (Thompson & Lawrie, 2017). With regard to BMPR2 acti-
vation, tacrolimus (FK506) was recently found to promote
BMPR2-Smad1/5/8 signalling by interacting with its pharmacological
target, 12-kDa FK506-binding protein (FKBP12), thereby removing
FKBP12 from all three BMP type 1 receptors (ALK1, ALK2, and
ALK3), including those preferred by BMPR2 (ALK1 and ALK3; Sitbon
et al., 2019). Tacrolimus prevented the development of PAH in mice
with endothelial deletion of BMPR2 and reversed established PAH in
two rat models (Spiekerkoetter et al., 2013). Compassionate treat-
ment with tacrolimus showed promising results in single patients with
IPAH (Spiekerkoetter et al., 2015) but did not attenuate the progres-
sion of PAH in a patient with an ALK1 mutation (Sommer et al., 2019).
A Phase 2 clinical trial of tacrolimus in patients with PAH showed
favourable safety, but efficacy signals were low (Spiekerkoetter
et al., 2017).
Another strategy to address TGFβ signalling involves inhibition of
the Smad 2/3 signalling pathway using sotatercept, an activin receptor
type 2A fusion protein that acts as a ligand trap. In a preclinical study,
sotatercept reversed pulmonary vascular remodelling and restored RV
function (Joshi, Liu, Pearsall, Li & Kumar, 2019). A Phase 2 open-label
study (SPECTRA; ClinicalTrials.gov identifier: NCT03738150) and a
Phase 2 RCT (PULSAR; ClinicalTrials.gov identifier: NCT03496207)
are currently recruiting patients with PAH. Primary outcomes will be
peak oxygen uptake and PVR respectively.
4.8.3 | Novel preclinical approaches
Smad ubiquitin regulatory factor 1 (SMURF-1) is involved in the deg-
radation of BMPR2 and different Smads and is up-regulated in PAH.
Nebulised administration of microRNA-140-5p, shown to target and
repress SMURF-1, attenuated PAH in rat models (Rothman
et al., 2016). Use of chloroquine to inhibit lysosomal degradation of
BMPR2 also restored BMPR2 signalling in vitro and prevented devel-
opment of monocrotaline-induced PH in rats (Long et al., 2013).
Application of recombinant BMP9 reversed PH in several animal
models, including a mouse model with a human loss-of-function muta-
tion in Bmpr2 (Long et al., 2015). By contrast, BMP9 deficiency or
inhibition prevented development of PH in mice exposed to chronic
hypoxia (Tu et al., 2019). It was recently argued that because of the
complexity of the BMP system, inhibition of endogenous BMP9 and
application of exogenous BMP9 may not be comparable and that inhi-
bition of endogenous BMP9 may inhibit muscularisation but also
induce an endothelial pathology similar to that observed in hereditary
haemorrhagic telangiectasia (Ormiston, Godoy, Chaudhary, &
Stewart, 2019).
Recently, fragile histidine triad (FHIT) was discovered as a novel
BMPR2 modifier by a high-throughput screen. FHIT works as a
tumour suppressor, and its expression is reduced in patients with
PAH. Up-regulation of FHIT by enzastaurin reversed PH in the Sug-
en/hypoxia rat model (Dannewitz Prosseda et al., 2019).
4.9 | Transcription factors
4.9.1 | PPAR-γ
PPAR-γ belongs to a group of nuclear receptor proteins and functions
as a transcription factor. When activated, PPAR-γ improves insulin
sensitivity and has anti-inflammatory properties. Both preclinical and
human studies have demonstrated the importance of PPAR-γ in PAH.
Activation of PPAR-γ signalling by rosiglitazone and pioglitazone
(PPAR-γ agonists used to treat Type 2 diabetes mellitus) inhibited
development of PH in animal models (reviewed in Prins et al., 2019).
However, despite the promising preclinical results, a clinical trial with
pioglitazone (ClinicalTrials.gov identifier: NCT00825266) was termi-
nated early. Furthermore, rosiglitazone has been withdrawn from the
market in certain countries due to suspected cardiovascular side
effects, and pioglitazone is suspected to cause bladder cancer. More-
over, the doses in preclinical PH studies were significantly higher than
the maximal doses used in patients (Prins et al., 2019). Nevertheless,
the quest for novel therapeutics exploiting PPAR-γ signalling con-
tinues. An inhaled therapy combining sildenafil and rosiglitazone was
successfully applied in rats with PH in a recently published study
(Rashid, Nozik-Grayck, McMurtry, Stenmark, & Ahsan, 2019).
4.9.2 | HIF and mechanistic target of rapamycin
signalling
Hypoxia causes pulmonary vasoconstriction, and hypoxic signalling is
also suspected to play a role in PAH. This concept is supported by the
finding of decreased expression of prolyl hydroxylase domain-
containing protein 2 (PHD2), which inhibits HIF, in PAEC from plexi-
form lesions, and by the fact that PHD2-deficient mice develop
severe, HIF-2α-dependent PH (Dai, Li, Wharton, Zhu, & Zhao, 2016).
Accordingly, the HIF-2α translation inhibitor C76 reduced PH in three
different rodent models (Dai et al., 2018). At least for hypoxia-induced
PH, HIF-1α also seems to be important (Ball et al., 2014).
One strategy to address HIF signalling is via inhibition of
mechanistic target of rapamycin (mTOR) which increases HIF expres-
sion. mTOR can act as a serine/threonine kinase or TK and is
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activated (for example) by growth factor receptors, but it also inte-
grates signals from high nutrient availability to regulate multiple cellu-
lar functions, such as proliferation, motility, survival, and cell cycle
progression (e.g., in T-cells). Thus, mTOR inhibitors such as rapamycin
are used as immunosuppressants, and clinical trials of rapamycin in
(for example) pancreatic cancers are currently ongoing. Inhibition of
mTOR reduced PH in several animal models (Goncharov et al., 2014;
Paddenberg et al., 2007). Moreover, PAH was recently improved in a
patient treated with rapamycin for pancreatic cancer (Wessler,
Steingart, Schwartz, Harvey, & Schaffer, 2010). Currently, a Phase
1 open-label clinical trial of ABI-009, an albumin-bound version of
rapamycin, is recruiting patients with severe PAH (ClinicalTrials.gov
identifier: NCT02587325).
4.9.3 | Novel preclinical targets
Another transcription factor with high potential as a therapeutic
target is FOXO1, which integrates several anti-proliferative and
pro-apoptotic signalling pathways in PASMC. Total FOXO1 levels
were decreased in animal models of PH and in human PAH, and
activation of FOXO1 reversed PH in animal models (Savai
et al., 2014). Targeting the FOXO1 pathway with paclitaxel—which
is currently used as a chemotherapeutic agent for different types
of cancer—could be a viable strategy for the treatment of PAH.
Many other transcription factors have been implicated in the devel-
opment of PH, including Notch receptor 3, STAT3, large tumour
suppressor 1 (central component of the Hippo pathway), myocyte
enhancer factor 2, tumour protein p53, kruppel-like factor
4, CCAAT-enhancer binding proteins, RUNX2, activator protein
1, NF-κB, β-catenin, the Twist family basic helix–loop–helix tran-
scription factor 1, and SLUG. Moreover, transcription factor
coactivators have also been implicated in the development of PH
(see Humbert et al., 2019; Pullamsetti et al., 2016).
5 | WHERE TO GO IN FUTURE?
There is consensus that PAH therapy must go beyond targeting pri-
marily vasodilation. Although a wide range of novel targets addressing
vascular and RV remodelling have been identified by preclinical stud-
ies, the challenge will be prioritising targets and designing clinical trials
for successful target validation. The success rate of clinical trial
programmes (measured as the proportion of drugs entering clinical
development that reach the marketplace) has decreased from 21% in
the early 1990s to 16%; about 50% of drugs entering clinical develop-
ment fail because of lack of efficacy (25% fail because of safety con-
cerns; Lythgoe et al., 2016). In order to prioritise targets, one has to
consider the set-up of the preclinical study with regard to limitations
of different animal models, species-specific pathways, and drug dose
requirements.
How can we overcome the gap between animal studies and
clinical trials? Considering the high success rate in animal models,
one should ask if the animal models oversimplify the patho-mecha-
nisms. The predominant stimulus in the chronic hypoxic animal
model is HIF-1 stabilisation, while the monocrotaline model is
largely driven by inflammation. By contrast, human PAH is trig-
gered by more than one stimulus acting over a long time period.
Multifactorial pathogenesis and individually varying pathways may
hamper disease targeting in individual patients (Lythgoe
et al., 2016; Provencher et al., 2018). Thus, the use of several ani-
mal models (possibly in a multicenter approach) and animal models
induced by more than one hit (e.g., Sugen/hypoxia or BMPR2
knockout plus hypoxia) might be a good step forward for preclini-
cal studies of potential PAH therapies, although animal models
reflecting end-stage disease are probably still lacking. The use of
mostly very young and often male mice for preclinical studies may
also be a limiting factor. Moreover, potential new therapies should
be tested on a background of existing PAH therapy, as most
patients in clinical trials will be pretreated with approved therapy.
Finally, one should consider that many pathways (particularly
immunological pathways, Mestas & Hughes, 2004, but also meta-
bolic pathways and distribution of specific vascular receptors and
enzymes) differ between mice and humans. Thus, transfer to the
human system at any step of research is mandatory and should
include more sophisticated models, such as organ culture, cultured
lung slices, or induced pluripotent stem cells to derive endothelial
cells. Nevertheless, animal models may offer optimal conditions to
identify specific pathways that trigger the disease in a particular
patient population.
Identifying the patient population which may profit most from a
specific treatment (“enrichment”) and applying individualised medicine
will allow successful targeting of very specific pathways (Sitbon
et al., 2019). Great efforts have been made in the past years using
genomics, epigenomics, and metabolomics to identify sub-clusters
within patient groups (Pulmonary Vascular Disease Phenomics
[PVDOMICS]; ClinicalTrials.gov identifier: NCT02980887). Thus, it
will be more important for future clinical trials to utilise biomarkers to
focus on specific patient subgroups (although this will further limit the
number of patients eligible for enrolment). Moreover, detailed patient
phenotyping can help to find pathways in common with animal stud-
ies and thus prioritise targets. Finally, specific effects of treatment on
the pulmonary vasculature and RV have to be taken into account in
future.
5.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Southan et al., 2016), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander, Christopoulos et al., 2019; Alexander, Cidlowski
et al., 2019; Alexander, Fabbro et al., 2019a, 2019b; Alexander, Kelly
et al., 2019a, 2019b).
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